Fenway Health Commends PUSPOSE 2 Twice Yearly HIV Pre-Exposure Prophylaxis (PrEP) Injection Study Re

Gilead announced today that the PURPOSE 2 study of twice yearly lenacapavir injections as pre-exposure prophylaxis (PrEP) reduced HIV infections by 96% compared ... Read more

Bron:

Events / Trade Shows